1,113
Views
23
CrossRef citations to date
0
Altmetric
Case Report

Tocilizumab Treatment for Nephrotic Syndrome Due to Amyloidosis in Behcet’s Disease

, , , , , & show all
Pages 547-550 | Received 17 Nov 2012, Accepted 01 Feb 2013, Published online: 11 Mar 2013

REFERENCES

  • Mendes D, Correia M, Barbedo M, . Behçet’s disease—a contemporary review. J Autoimmun. 2009;32:178–188.
  • Belmouaz S, Sechet A, Fernandez B, . Tubulo-interstitial nephritis with Fanconi syndrome in Behçet disease. Nephrol Dial Transplant. 2007;22:2079–2083.
  • Magro-Checa C, Navas-Parejo Casado A, Borrego-García E, . Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis. Amyloid. 2011;18:235–239.
  • Sahin I, Noyan T, Karaman E, Yalçmkaya AS, Metin A, Akpolat T. Mild renal injury in Behçet´s Disease. Ren Fail. 2004;26:55–57.
  • Nadir I, Gültekin F, Yönem O, Yildiz EA. Behçet case with renal amyloidosis. Ren Fail. 2003;25:323–326.
  • Kutlay S, Civriz S, Ensari A, Nergizoglu G, Ates K, Karatan O. Development of amyloidosis in Behçet’s syndrome with isolated mucocutaneous involvement. Rheumatol Int. 2004;24:37–39.
  • Kosemehmetoglu K, Baydar DE. Renal amyloidosis in Behçet´s disease: clinicopathologic features of 8 cases. Int Urol Nephrol. 2012; Sep 9. [Epub ahead of print].
  • Akpolat T, Dilek M, Aksu K, . Renal Behçet’s disease: an update. Semin Arthritis Rheum. 2008;38:241–248.
  • Skhiri H, Mahjoub S, Harzallah O, . Secondary amyloidosis, a fatal complication of Behçet´disease: three case reports. Saudi J Kidney Dis Transpl. 2004;15:57–60.
  • Melikoglu M, Altiparmak MR, Fresko I, . A reappraisal of amyloidosis in Behçet´syndrome. Rheumatology. 2001;40:212–215.
  • Pay S, Simşek I, Erdem H, Dinç A. Immunopathogenesis of Behçet’s disease with special emphasize on the possible role of antigen presenting cells. Rheumatol Int. 2007;27:417–424.
  • Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol. 2002;31:205–210.
  • Evereklioglu C, Er H, Türköz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease. Mediators Inflamm. 2002;11:87–93.
  • Hirano T, Ohguro N, Hohki S, . A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22:298–302.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.